WO1998055491A1 - Process for preparing etoposide - Google Patents
Process for preparing etoposide Download PDFInfo
- Publication number
- WO1998055491A1 WO1998055491A1 PCT/US1998/007717 US9807717W WO9855491A1 WO 1998055491 A1 WO1998055491 A1 WO 1998055491A1 US 9807717 W US9807717 W US 9807717W WO 9855491 A1 WO9855491 A1 WO 9855491A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- etoposide
- reaction
- product
- anomer
- Prior art date
Links
- 0 COc1cc([C@@](C([C@@](CO2)[C@@](c3c4)O)C2=O)c3cc2c4OCO2)cc(*)c1O Chemical compound COc1cc([C@@](C([C@@](CO2)[C@@](c3c4)O)C2=O)c3cc2c4OCO2)cc(*)c1O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a novel process for preparing the anticancer compound, etoposide, in the C-l"- ⁇ anomeric form, as well as a novel intermediate compound.
- Etoposide (VP-16) The key step in this process is the coupling reaction. It is generally accomplished by attack of the anomeric oxygen of the sugar on a BF3-OEt2 generated C-4 lignan carbocation, which can give a mixture of C-l"- ⁇ and - ⁇ anomers.
- prior art teaches making a sugar which is mostly ⁇ so the reaction will proceed predominantly with retention of the ⁇ -anomeric configurationl'- ⁇ A
- ether protecting groups are rare because the ⁇ sugars are not readily made (e.g. 2,3,4,6-tetra-O-benzyl- ⁇ -D- glucopyranose has never been reported).
- a benzyl ether protecting group offers the advantage of mild, neutral conditions for deprotection.
- novel intermediate products form unexpectedly with good selectivity, and then, due to the presence of BF 3 , OEt2 surprisingly and unexpectedly epimerize from ⁇ to ⁇ , presumably via a reversible reaction driven by precipitation of the ⁇ product, giving very high selectivity (>44:1).
- the input sugar does not need to be high in ⁇ - anomeric content to achieve high selectivity in the coupling.
- the product is easily isolated and purified by recrystallization. Deprotection of the hydroxyl groups, preferably by hydrogenation under mild conditions readily affords etoposide in high yield and purity.
- the present invention is directed to a process for preparing the compound etoposide 4 having the structure
- step (c) removing the hydroxy-protecting groups from the product of step (b).
- a preferred embodiment is the aforementioned process wherein said solvent is halogenated or non-halogenated, more preferably, acetonitrile.
- Another preferred embodiment is the aforementioned process wherein said hydroxy-protecting groups are removed by hydrogenation at ambient temperature in the presence of a noble metal catalyst.
- the noble metal catalyst is palladium.
- the Lewis acid is boron trifluoride etherate.
- the reaction is carried out at about room temperature to -40°C, more preferably at 0°C to -40°C, and still more preferably at -10°C.
- the present invention is also directed to a process of obtaining the C-l"- ⁇ anomer of compound 3 comprising forming a solution of an anomeric mixture of compound 3 in an organic solvent, recovering the resulting precipitated product that forms, forming a second solution of said recovered product in an alcohol, crystallizing said C-l"- ⁇ anomer from said second solution and recovering crystals of said C-l"- ⁇ anomer substantially free of ⁇ anomer.
- the alcohol is methanol.
- the present invention is also directed to novel intermediate compounds 3 ⁇ , ⁇ having the formula
- the compound 3 is the C-l"- ⁇ anomer. DETAILED DESCRIPTION OF THE INVENTION
- the present invention described herein relates to a novel methodology for the synthesis of etoposide 4 from 4'-demethyl-4- epipodophyllotoxin 1.
- R 1 -H, -C(0)R or -C(0)OR ;
- R 2 --*-- C(0)R or- C(0)OR ;
- R 4 R or ethylidene acetal
- the process disclosed herein uses 2 as the sugar or carbohydrate component.
- the required sugar 2 was prepared by adaptation of known literature methods for analogous compounds.
- the mixture of anomers of 2 may be converted to a mixture that is >85% ⁇ . This involves either a) recrystallization from hexanes or heptane; b) allowing the oily mixture of anomers to stand at room temperature for 2 months; or c) recrystallizing from methanol/water and then heating the solid below it's melting point for a period of 1-7 days.
- the anomerically pure sugar 2 ⁇ is not required in the coupling step used herein.
- the initial anomeric ratio of products is dependent on the initial anomeric composition of compound 2. If starting compound 2 is >90% ⁇ , the ratio for coupled product 3 at -40(C is about 8:2 ⁇ : ⁇ . If the input sugar 2 is 63:37, the initial coupled product 3 ratio is 61:39.
- the ⁇ : ⁇ ratio of the products unexpectedly increases. If the products remain in solution, a thermodynamic equilibrium will be established between the two products 3 ⁇ and 3 ⁇ . This is presumably caused by a reversible uncoupling of the sugar, followed by rapid recoupling. In this specific case, however, the product 3 ⁇ precipitates preferentially due to lower solubility from the acetonitrile. The product remaining in the solution (presumably mostly ⁇ ) then reestablishes the equilibrium, driving the reaction towards the ⁇ product. This theory was demonstrated in a reaction in which the product did not precipitate rapidly and the ratio of products moved toward the ⁇ . When it finally did precipitate, the ratio moved back towards ⁇ .
- Compound 2 that is not high in ⁇ content may be used, although the reaction may take more time to reach the higher ratios. Ratios as high as 97.8:2.2 ⁇ : ⁇ have been reached. Seeding of the solution with pure 3 ⁇ also aids in the precipitation of the product thereby lowering the overall reaction time.
- 2,3-hydroxy-protecting groups on glucopyranose compound 2 be benzyl (i.e. Ri is benzyl), it is contemplated that other aryl methyl groups can be used.
- substituted benzyl that is substituted with one or more selected from the group consisting of C1-4 alkyl, hydroxy, phenyl, benzyl, halogen such as fluoro, chloro, bromo and iodo, alkoxy, nitro and carboxylic acids and esters thereof.
- Suitable substituted benzyl groups include 2-methyl benzyl, 3- methyl benzyl, 4-methyl benzyl, 1 or 2-naphthyl, 2, 3 or 4-phenyl benzyl, 4- methoxy carbonyl benzyl, 2,6-dichlorobenzyl, 2-fluorobenzyl and pentafluorobenzyl.
- the glucopyranose may further have the structure of Compound 2a
- Ri is as above and R2 is the same as Ri, or the two R2 groups taken together are a C 1 -5 alkylidene group.
- the two R2 groups together are ethylidene.
- the two R2 groups together may be propylidene or isopropylidene.
- the product 3 can be isolated directly by filtration of the reaction mixture. This yields a crude solid in a weight yield of 95% and a purity of -90%. There is a small amount of 3 ⁇ . This isolation gives much better results than Wang's or Allevi's methods.
- the solid 3 is then recrystallized by dissolving in methylene chloride, adding methanol, distilling off most of the methylene chloride, and cooling. 3fi is obtained in 78.6% yield with purity >99%. This yield is higher than Wang's
- the initial ratio of C-l"-fi: ⁇ in the coupled products is affected by numerous factors, including temperature and solvent.
- the Lewis acid used in the coupling step can be for example AICI3, ZnCl 2 , Et 2 AlCl, CF3SO3H, CF 3 S0 3 Ag, Zn(CF 3 S0 3 ) 2 , TMSCF3SO3 and boron trifluoride etherate.
- it is boron trifluoride etherate.
- the organic solvent used as a reaction medium may be halogenated or non-halogenated. Examples are propionitrile, acetone, methylene chloride, chloroform, 1,2-dichloroethane, acetonitrile and mixtures thereof.
- the preferred solvent for the coupling reaction is acetonitrile since it alows for direct crystallization of the 3 ⁇ product therefore allowing for purification to drive the reaction to the desired product.
- the coupling reaction is generally carried out at or below room temperature and preferably at about 0°C to -40°C. Preferred temperature is -10°C. 2.
- the hydroxy protecting groups are removed by known methods and preferably by hydrogenation.
- the hydrogenation deprotection step proceeds efficiently to produce etoposide in high yield with minimal degradation.
- Compound 3 is very labile and sensitive to both acid and base. Existing processes of using acids or bases to remove the hydroxy protective groups usually result in decomposition of a portion of the desired product.
- the deprotection steps can cleave the ethylidene group from the glucopyranose.
- the hydrogenation may be accomplished by a number of known processes. Typically, the hydrogenation is done in the presence of a noble metal catalyst in a suitable solvent or solvent mixture.
- the hydrogenation is carried out using
- the protecting groups are preferably removed by hydrogenation over a Pd/C catalyst.
- a yield of 96.8% has been obtained.
- the process has the following advantages: a) it is a short and efficient synthesis of etoposide without any chromatographic purification; b) the compound 1 phenol during the coupling reaction is unprotected and the sugar protecting groups on resulting compound 3 ⁇ are removed readily in high yield (the overall yield for the two steps is 79.3% - Allevi reports 35.7% 3b and 70% 3 overall, Wang 54% 3a ); c) very high ⁇ : ⁇ ratios of coupled product 3 can be obtained even when starting from a sugar 2 of moderate ⁇ : ⁇ ratio, in view of the novel epimerization of 3 ⁇ to 3 ⁇ ; and d) it is not necessary to make C-l derivatives on sugar compound 2 prior to coupling, as is taught by Allevi 3c ' d (e.g. using 1-O- ⁇ -trimethylsilyl sugars).
- HPLC after 17 min showed 15% 1, 19% 3 ⁇ , and 54% 3 ⁇ .
- the slurry was stirred at -40°C for 18 h, and pH 7 buffer (Fisher, 0.05 M KH2PO4, 222 ml) was added. The mixture was allowed to warm to between 0°C and room temperature. The solid was collected by vacuum filtration, washed twice with water and dried under vacuum (40°C). The crude white solid (9.42 g, 98.1%) thus obtained had an area percent of 85.1% by HPLC.
- the solid was dissolved in CH2CI2 (56.4 ml) and one percent methanol (282 ml) was added slowly while warming and the solution stirred.
- the mixture was warmed to reflux and distilled at atmospheric pressure until 56 ml distllate was collected.
- the mixture was allowed to cool to room temperature, then cooled in an ice bath for 2 h.
- the white crystals were collected by vacuum filtration and washed twice with cold methanol.
- the solid was dried in the vacuum oven (40°C, house vacuum) overnight. 7.06 g (73.6% yield) of 3 ⁇ was obtained with a 99J.
- the area percent was 99J as determined by HPLC.
- the product was collected by vacuum filtration and washed with cold acetonitrile (50 ml). The wet cake was dissolved in dichloromethane (150 ml) and then concentrated to 100 ml. Methanol (300 ml) was added and the dichloromethane was distilled off at atmospheric pressure. The volume was maintained at 325 ml by addition of methanol. The slurry was cooled to 20 °C and stirred for one hour and then cooled to 0 °C and stirred for two hours. The product was collected and washed with cold methanol. The solid was dried in the vacuum oven at 45 °C to yield 14.08 g (81.9% yield) of 3 ⁇ .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69818460T DE69818460T2 (en) | 1997-06-02 | 1998-04-17 | METHOD FOR PRODUCING ETOPOSIDE |
JP50238999A JP4698775B2 (en) | 1997-06-02 | 1998-04-17 | Method for producing etoposide |
KR10-1999-7010912A KR100519498B1 (en) | 1997-06-02 | 1998-04-17 | Process for preparing etoposide |
IL13231998A IL132319A (en) | 1997-06-02 | 1998-04-17 | Process for preparing etoposide |
HU0002670A HU228520B1 (en) | 1997-06-02 | 1998-04-17 | Process for preparing etoposide |
CA002288898A CA2288898A1 (en) | 1997-06-02 | 1998-04-17 | Process for preparing etoposide |
AU71276/98A AU728986B2 (en) | 1997-06-02 | 1998-04-17 | Process for preparing etoposide |
EP98918330A EP0986569B1 (en) | 1997-06-02 | 1998-04-17 | Process for preparing etoposide |
AT98918330T ATE250620T1 (en) | 1997-06-02 | 1998-04-17 | METHOD FOR PRODUCING ETOPOSIDE |
HK00104845A HK1025576A1 (en) | 1997-06-02 | 2000-08-02 | Process for preparing etoposide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4829297P | 1997-06-02 | 1997-06-02 | |
US60/048,292 | 1997-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998055491A1 true WO1998055491A1 (en) | 1998-12-10 |
Family
ID=21953762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/007717 WO1998055491A1 (en) | 1997-06-02 | 1998-04-17 | Process for preparing etoposide |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0986569B1 (en) |
JP (1) | JP4698775B2 (en) |
KR (1) | KR100519498B1 (en) |
AT (1) | ATE250620T1 (en) |
AU (1) | AU728986B2 (en) |
CA (1) | CA2288898A1 (en) |
DE (1) | DE69818460T2 (en) |
ES (1) | ES2206917T3 (en) |
HK (1) | HK1025576A1 (en) |
HU (1) | HU228520B1 (en) |
IL (1) | IL132319A (en) |
TW (1) | TW491850B (en) |
WO (1) | WO1998055491A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757138A (en) * | 1984-05-22 | 1988-07-12 | Nippon Kayaku Kabushiki Kaisha | Process for producing etoposide |
US5036055A (en) * | 1989-06-07 | 1991-07-30 | Bristol-Myers Company | Acylated derivatives of etoposide |
US5206350A (en) * | 1990-06-07 | 1993-04-27 | Shanghai Institute Of Pharmaceutical Industry | Synthetic process for the preparation of anti-tumor agent-etoposide |
US5459248A (en) * | 1993-11-04 | 1995-10-17 | Bristol-Myers Squibb Company | Process of preparing etoposide phosphate and etoposide |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59212500A (en) * | 1983-05-18 | 1984-12-01 | Nippon Kayaku Co Ltd | Novel process for preparation of 4'-demethyl- epipodophyllotoxin-beta-d-ethylydene glucoside |
DE3913326A1 (en) * | 1989-04-22 | 1990-11-08 | Behringwerke Ag | METHOD FOR PRODUCING ETOPOSIDES |
JPH02191294A (en) * | 1989-12-08 | 1990-07-27 | Nippon Kayaku Co Ltd | Acyl derivative of 4'-dimethyl-epipodophyllotoxin-beta-d-ethylidene glucoside |
FR2658824B1 (en) * | 1990-02-27 | 1992-07-03 | Pf Medicament | TRIS ACETYL-2 ", 3", 4 'ETHYLIDENE-4 ", 6" BETA-D-GLUCOPYRANOSIDES, THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF DEMETHYL-4' EPIPODOPHYLLOTOXIN ETHYLIDENE BETA-D-GLUCOPYRANOSIDE. |
IT1250692B (en) * | 1991-07-23 | 1995-04-21 | PROCEDURE FOR THE PREPARATION OF DEMETYLEPIPODOPHYLOTOXY-BETA-D-GLUCOSIDES. |
-
1998
- 1998-04-17 WO PCT/US1998/007717 patent/WO1998055491A1/en active IP Right Grant
- 1998-04-17 DE DE69818460T patent/DE69818460T2/en not_active Expired - Lifetime
- 1998-04-17 CA CA002288898A patent/CA2288898A1/en not_active Abandoned
- 1998-04-17 IL IL13231998A patent/IL132319A/en not_active IP Right Cessation
- 1998-04-17 EP EP98918330A patent/EP0986569B1/en not_active Expired - Lifetime
- 1998-04-17 AU AU71276/98A patent/AU728986B2/en not_active Expired
- 1998-04-17 HU HU0002670A patent/HU228520B1/en unknown
- 1998-04-17 AT AT98918330T patent/ATE250620T1/en active
- 1998-04-17 JP JP50238999A patent/JP4698775B2/en not_active Expired - Lifetime
- 1998-04-17 ES ES98918330T patent/ES2206917T3/en not_active Expired - Lifetime
- 1998-04-17 KR KR10-1999-7010912A patent/KR100519498B1/en not_active IP Right Cessation
- 1998-05-29 TW TW087108477A patent/TW491850B/en not_active IP Right Cessation
-
2000
- 2000-08-02 HK HK00104845A patent/HK1025576A1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757138A (en) * | 1984-05-22 | 1988-07-12 | Nippon Kayaku Kabushiki Kaisha | Process for producing etoposide |
US5036055A (en) * | 1989-06-07 | 1991-07-30 | Bristol-Myers Company | Acylated derivatives of etoposide |
US5206350A (en) * | 1990-06-07 | 1993-04-27 | Shanghai Institute Of Pharmaceutical Industry | Synthetic process for the preparation of anti-tumor agent-etoposide |
US5459248A (en) * | 1993-11-04 | 1995-10-17 | Bristol-Myers Squibb Company | Process of preparing etoposide phosphate and etoposide |
US5688926A (en) * | 1993-11-04 | 1997-11-18 | Bristol-Myers Squibb Company | Process of preparing etoposide phosphate and etoposide |
Also Published As
Publication number | Publication date |
---|---|
ES2206917T3 (en) | 2004-05-16 |
HUP0002670A3 (en) | 2003-05-28 |
EP0986569A4 (en) | 2002-01-09 |
JP2002514223A (en) | 2002-05-14 |
ATE250620T1 (en) | 2003-10-15 |
JP4698775B2 (en) | 2011-06-08 |
AU728986B2 (en) | 2001-01-25 |
EP0986569B1 (en) | 2003-09-24 |
KR100519498B1 (en) | 2005-10-07 |
HUP0002670A2 (en) | 2000-12-28 |
CA2288898A1 (en) | 1998-12-10 |
IL132319A0 (en) | 2001-03-19 |
IL132319A (en) | 2003-07-06 |
DE69818460T2 (en) | 2004-07-01 |
DE69818460D1 (en) | 2003-10-30 |
HK1025576A1 (en) | 2000-11-17 |
KR20010012942A (en) | 2001-02-26 |
HU228520B1 (en) | 2013-03-28 |
TW491850B (en) | 2002-06-21 |
AU7127698A (en) | 1998-12-21 |
EP0986569A1 (en) | 2000-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU594502B2 (en) | Sucrose derivatives | |
RU2439064C1 (en) | METHOD OF PRODUCING CAPECITABINE AND β-ANOMER RICH TRIALKYLCARBONATE COMPOUND USED THEREIN | |
US4340729A (en) | 5'-Deoxy-5-fluorouridine | |
JP3231765B2 (en) | Method for producing demethyl epipodophyllotoxin | |
US5066645A (en) | Epipodophyllotoxin altroside derivatives | |
US5459248A (en) | Process of preparing etoposide phosphate and etoposide | |
KR100908363B1 (en) | Stereoselective preparation method of tri-O-acetyl-5-deoxy-β-D-ribofuranose and separation method thereof | |
EP0986569B1 (en) | Process for preparing etoposide | |
HU198505B (en) | Process for producing antitumour anthracycline glycosides | |
US5262531A (en) | Process for preparing 2'-deoxy-β-adenosine | |
HU208835B (en) | Process for producing 2",3",4'-tris-(acetyl)-4",6"-ethylidene-beta-d-glycopyranozides | |
US5220002A (en) | Deacetylcolchicine derivatives | |
DE DK et al. | VERFAHREN ZUR HERSTELLUNG VON ETOPOSID PROCEDE DE PREPARATION D’ETOPOSIDE | |
EP1140962B1 (en) | Novel derivatives from the class of oleandomycin | |
CA1151160A (en) | Erythromycylamine 11,12-carbonate and derivatives thereof | |
CA2104476A1 (en) | New and improved solvent-free synthesis of ethereally substituted blocked monosaccharides and the selective hydrolysis_thereof | |
JP2000512273A (en) | High yield stereospecific mannosylation | |
JP3258914B2 (en) | Method for producing erythromycin derivative | |
KR0130942B1 (en) | Preparation process of 3-azido-3-deoxythimidine | |
WO1992006986A1 (en) | Process for producing d-altrose | |
HU215156B (en) | Process for producing 4'-dezoxy-10,11,12,13-tetrahydro-demicosin and pharmaceutical compositions containing it | |
HU221982B1 (en) | Glucopiranose intermediate for the synthesis of etoposide phosphate and etoposide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 132319 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2288898 Country of ref document: CA Ref country code: CA Ref document number: 2288898 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/010234 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997010912 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 71276/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998918330 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998918330 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997010912 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 71276/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998918330 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997010912 Country of ref document: KR |